In the quiet chemistry of digestion, trillions of gut microbes transform an ordinary nutrient into a compound that may quietly destabilize the heart's electrical order. Researchers have traced a molecular pathway from dietary choline through bacterial metabolism to a metabolite called TMAO, finding it independently associated with atrial fibrillation in a cohort of over five thousand people and causally linked to arrhythmia in animal models. The discovery positions the gut microbiome not merely as a digestive actor but as an unsuspected participant in cardiac rhythm — and, crucially, as a pote
Gut Microbe Metabolite TMAO Linked to Atrial Fibrillation Risk in Humans and Mice
Cobertura Relacionada
The Smithsonian Institution has used advanced genomics on Thomas Jefferson's hair to provide definitive proof he fathere…
Mashable · Sep 19 Moon in Waxing Gibbous phase on Sept. 19; Full Moon arrives Sept. 26The Moon enters its Waxing Gibbous phase on September 19, 2026, with 54% illumination visible before reaching Full Moon …
EurekAlert! · Sep 19 Tokyo researchers optimize ultra-thin wings for Mars drones using bio-inspired designTokyo Metropolitan University researchers used evolutionary algorithms to design ultra-thin, corrugated airfoils optimiz…
ScienceDaily · Sep 19 First Diplodocus fossil found outside North America discovered in SpainSpanish paleontologists identified a 150-million-year-old Diplodocus fossil from the Late Jurassic period, the first con…
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
This is a medical research article about gut microbiota and heart disease, not a geopolitical issue requiring international relations analysis.
Lente Económico
Research linking gut microbe metabolite TMAO to atrial fibrillation opens new therapeutic markets in microbiome-targeted drugs and dietary interventions, with potential to reduce cardiovascular disease burden.
Consumers may face increased demand for TMAO-reducing dietary products, probiotic supplements, and choline-restricted foods. Healthcare costs could decrease long-term if therapeutic interventions prevent AF, but short-term costs may rise from new diagnostic testing and treatments.
FDA may accelerate approval pathways for microbiome-targeted therapeutics. Regulatory bodies may require TMAO labeling on high-choline foods. Healthcare systems may implement TMAO screening protocols. Reimbursement policies for preventive microbiome interventions will likely evolve.